Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation - Wikidata - thesis-toulmin - TriplyDB

Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation

Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation

http://www.wikidata.org/entity/Q24634808

about

Dynorphin--still an extraordinarily potent opioid peptide κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction Kappa Opioids, Salvinorin A and Major Depressive Disorder Characterization of BU09059: a novel potent selective κ-receptor antagonist Salvinorin A administration after global cerebral hypoxia/ischemia preserves cerebrovascular autoregulation via kappa opioid receptor in piglets Corticotropin-releasing factor (CRF)-induced disruption of attention in rats is blocked by the κ-opioid receptor antagonist JDTic.Constitutive activation of kappa opioid receptors at ventral tegmental area inhibitory synapses following acute stress.Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity Selective κ opioid antagonists nor-BNI, GNTI and JDTic have low affinities for non-opioid receptors and transporters.BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice.The kappa opioid receptor: from addiction to depression, and back.In vivo and in vitro characterization of naltrindole-derived ligands at the κ-opioid receptor Potency enhancement of the κ-opioid receptor antagonist probe ML140 through sulfonamide constraint utilizing a tetrahydroisoquinoline motif Mu opioid receptor stimulation activates c-Jun N-terminal kinase 2 by distinct arrestin-dependent and independent mechanisms.The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety.Semisynthetic neoclerodanes as kappa opioid receptor probes.Effects of acute and chronic social defeat stress are differentially mediated by the dynorphin/kappa-opioid receptor system.A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic.Functional selectivity of kappa opioid receptor agonists in peripheral sensory neurons.Ligand-directed signalling within the opioid receptor family.Development of κ opioid receptor antagonists.The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting κ opioid receptor antagonism in the CNS after oral administration.Two short-acting kappa opioid receptor antagonists (zyklophin and LY2444296) exhibited different behavioral effects from the long-acting antagonist norbinaltorphimine in mouse anxiety tests Species differences in the effects of the κ-opioid receptor antagonist zyklophin.Molecular mechanisms of opioid receptor-dependent signaling and behavior.Mu opioids and their receptors: evolution of a concept.Stress-Induced Reinstatement of Nicotine Preference Requires Dynorphin/Kappa Opioid Activity in the Basolateral Amygdala.Dissociating Motivational From Physiological Withdrawal in Alcohol Dependence: Role of Central Amygdala κ-Opioid Receptors.Studies toward bivalent κ opioids derived from salvinorin A: heteromethylation of the furan ring reduces affinity.Nicotine Increases Alcohol Intake in Adolescent Male Rats The discovery and development of the N-substituted trans-3,4-dimethyl-4-(3'-hydroxyphenyl)piperidine class of pure opioid receptor antagonists.The orexin 1 receptor modulates kappa opioid receptor function via a JNK-dependent mechanism.Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and Without Cocaine Dependence.Long-Term Reduction of Kappa Opioid Receptor Function by the Biased Ligand, Norbinaltorphimine, Requires c-Jun N-Terminal Kinase Activity and New Protein Synthesis in Peripheral Sensory Neurons.Kappa opioid receptor antagonism and chronic antidepressant treatment have beneficial activities on social interactions and grooming deficits during heroin abstinence.Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.Peroxiredoxin 6 mediates Gαi protein-coupled receptor inactivation by cJun kinase."Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats".Biased signalling: from simple switches to allosteric microprocessors.

P2860

Q26860519-A9110739-6DDC-4789-A0F9-2646405701E8 Q26864309-40B191E0-392D-40D1-8DE0-CDB4BDF03EDF Q28075656-6C7F49C9-3DFF-4FCA-9CC1-2B7BD1B6B33C Q28305606-E65E8686-9402-40B2-B21C-8296F2E58CAA Q28481482-4AB6A0E6-7A00-42B6-85B3-7831774311BF Q30446679-1C70B138-1488-43FB-A996-0EBCF1F139F2 Q33558914-F2A92CC0-2E09-4B57-9A0C-D75EE8D01092 Q33860286-82CE9EA9-A657-4A0A-BC08-4316D6DB7922 Q34285100-6862BFCA-0627-4889-A988-2F221B3290C1 Q34366661-0A821701-DF60-4724-A6B4-597917DD288E Q34423181-F19CA70B-D9A7-4E09-A338-CD28C6F5142B Q34650892-898AFA8C-417F-428A-8FF1-B645E60660BB Q35182618-FD32E3B4-5ABA-4542-A34C-B05E0DA8C863 Q35744300-A24C2D5B-115A-491B-9FF6-B7EDB366847E Q35822876-F4FF9F94-ECE5-4D4D-9955-D9BAF404AECC Q35906830-22C05836-0D58-41EC-987A-9ACAADAB885F Q35935443-E9EB259E-C1B8-4E16-A1E1-A1A3370850A8 Q36101215-A5C3BE18-979E-4C4E-8AC8-03DF5EBDE54C Q36184879-3DB63324-47C9-448C-A81B-62CF41B27BC3 Q36186182-2F1F3AB7-D506-42BF-8129-D735D42534D9 Q36382935-4B6E39C5-6603-40FB-B147-39125E6AB34C Q36728154-49B1BD47-AF64-43A1-8819-F2D9376110F0 Q36836438-C5D6AA70-770A-4765-B802-96331ED44137 Q36924403-39110EDD-54D5-4895-AB0B-F4BFD6FE1167 Q36934953-6AF1DDB7-57A7-44D3-A29F-74769CCFB4AD Q36974487-F5EE8768-FEA9-4B9E-9901-706D0F2F1608 Q37236111-BE813E79-DD53-4516-89E6-EC7193E877ED Q37270938-EA3D2ED1-6723-450B-8DCC-A47F1845F058 Q37458269-F5EB488C-D67E-433F-A3AD-59F53E2B87F8 Q37495486-051BD36B-FEC7-44B1-A5FE-E8F947506D01 Q37656941-B10576ED-B5A2-4A6A-8922-2BD0D426A7D0 Q38225032-95F8E0F2-F7D9-42D1-9B15-FE640FE18945 Q38444486-D525CB04-FCAB-4334-8AE7-73652852D76F Q38600702-713FE7A6-52A0-4756-BF20-EE2A6EA55F52 Q39412016-09A23AC4-B0D9-4135-A514-BFC5228B29B0 Q41505543-09321B17-C672-4DAE-9A21-9C8AAECE5C66 Q41639865-159077DE-7DDF-40DA-9046-DE3D1898E820 Q42164005-3C9177D5-7CBE-4988-B51A-AF61119418B4 Q44345977-86F83633-6DCB-43FD-A46C-07F0FE66B868 Q47231111-3E1B11B6-AB69-4502-A36C-0B660D61A0D3

P2860

Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation

http://www.wikidata.org/entity/Q24634808

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Duration of action of a broad ...... N-terminal kinase-1 activation

@ast

Duration of action of a broad ...... N-terminal kinase-1 activation

@en

Duration of action of a broad ...... N-terminal kinase-1 activation

@nl

type

label

Duration of action of a broad ...... N-terminal kinase-1 activation

@ast

Duration of action of a broad ...... N-terminal kinase-1 activation

@en

Duration of action of a broad ...... N-terminal kinase-1 activation

@nl

prefLabel

Duration of action of a broad ...... N-terminal kinase-1 activation

@ast

Duration of action of a broad ...... N-terminal kinase-1 activation

@en

Duration of action of a broad ...... N-terminal kinase-1 activation

@nl

P1433

Q24634808-2332CC40-5681-47ED-A3E7-E9F4E3565F0C

P1476

Q24634808-16C281E7-BB62-4C61-9AB5-B190A26A3E94

P2093

Q24634808-080E499C-3FDA-4037-8396-F1BDBF48ACEB

Q24634808-17A56506-B752-45E4-8CA9-26E5E4449F00

Q24634808-2CD33589-C087-481B-8E5E-B2271E83005B

Q24634808-3DF172C3-9740-4821-BFCA-CEA9ACC2DBA3

Q24634808-594B4385-D5CE-438F-B803-231822DD5846

Q24634808-71CF8296-1DC5-4D53-A6CA-D5B20C565B7F

Q24634808-827B69A7-7F86-421A-8E56-6F472AEBEE8C

Q24634808-C66A0009-A957-40C9-9A56-0DAFFA39AAE3

Q24634808-CAE0AE0B-990C-4CF3-A91C-31695E80A384

Q24634808-E6014F94-C420-49F1-A9AA-7369F1863F25

P2860

Q24634808-03AC44F6-449F-485D-B073-34393C8D323A

Q24634808-2D38AC4A-C83E-4AAD-AE9F-7ABD65DA4B69

Q24634808-31BC0334-C146-4B47-8A4C-0367BD4C232A

Q24634808-357B4200-7FE7-4ADC-AD9F-979FE0646939

Q24634808-36FFE921-4675-4D01-8510-516F28EDB0F7

Q24634808-3C1E4124-CC29-44BE-8220-90472C370F6E

Q24634808-3D870F7C-E1AC-40EF-9116-22A5D5F79C08

Q24634808-47914BF2-5BDA-4B89-B4AB-8983986B8BC3

Q24634808-4C827AFA-0B22-4B71-8FD8-976ED4670026

Q24634808-558F9A34-D772-456C-8C4D-D608F1BE41F8

P304

Q24634808-A640EAD7-62A7-4B06-8BD3-3C5698C4F5ED

P31

Q24634808-A174201A-4F69-48E3-AE22-286C582BA0A7

P356

Q24634808-BE33B830-F58E-4505-A9E0-D28520953C71

P407

Q24634808-D1EFFCA9-09EF-4AE7-86E3-BDA1EA2E04E3

P433

Q24634808-6C74225D-DAF2-46F5-8A3B-EB61AAE95120

P478

Q24634808-6F86C1FB-6A93-4C51-8784-FEB20FD6B9B3

P577

Q24634808-6C9DC8B0-C172-4E4B-AF70-BAAC74E62DF9

P5875

Q24634808-E23B61AB-9C50-4F45-A47B-3D8B41C43A39

P698

Q24634808-BB5E4B58-DA6A-4E79-8210-65B2B15B1B82

P921

Q24634808-3b668780-d811-4e45-b06a-c74071a11757

P932

Q24634808-B5458F5A-DC2A-4F76-BBC4-498EC17EFB30

P356

P1433

Molecular Pharmacology

P1476

Duration of action of a broad ...... N-terminal kinase-1 activation

@en

P2093

Bruce M Cohen

http://www.w3.org/2001/XMLSchema#string

Charles Chavkin

http://www.w3.org/2001/XMLSchema#string

Charles H Mitch

http://www.w3.org/2001/XMLSchema#string

Cécile Béguin

http://www.w3.org/2001/XMLSchema#string

Erica J Melief

http://www.w3.org/2001/XMLSchema#string

F Ivy Carroll

http://www.w3.org/2001/XMLSchema#string

Linda Rorick-Kehn

http://www.w3.org/2001/XMLSchema#string

Mayumi Miyatake

http://www.w3.org/2001/XMLSchema#string

Sarah Grimwood

http://www.w3.org/2001/XMLSchema#string

William A Carlezon

http://www.w3.org/2001/XMLSchema#string

P2860

Functional Selectivity and Classical Concepts of Quantitative Pharmacology

The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system

Kappa-opioid ligands in the study and treatment of mood disorders

Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses

Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase

Signal transduction by the JNK group of MAP kinases

Effector antagonism by the regulators of G protein signalling (RGS) proteins causes desensitization of mu-opioid receptors in the CNS

Activation of mu-opioid receptors transfers control of Galpha subunits to the regulator of G-protein signaling RGS9-2: role in receptor desensitization

Phosphorylation of a carboxyl-terminal serine within the kappa-opioid receptor produces desensitization and internalization

Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking.

P304

920-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/MOL.111.074195

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

80

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51562381

http://www.w3.org/2001/XMLSchema#string

P698

21832171

http://www.w3.org/2001/XMLSchema#string

P921

P932

3198912

http://www.w3.org/2001/XMLSchema#string